Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

Nandu Thalange, Larry Deeb, Violeta Iotova, Tomoyuki Kawamura, Georgeanna Klingensmith, Areti Philotheou, Janet Silverstein, Stefano Tumini, Ann-Marie Ocampo Francisco, Ona Kinduryte, Thomas Danne, Nandu Thalange, Larry Deeb, Violeta Iotova, Tomoyuki Kawamura, Georgeanna Klingensmith, Areti Philotheou, Janet Silverstein, Stefano Tumini, Ann-Marie Ocampo Francisco, Ona Kinduryte, Thomas Danne

Abstract

Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily, with prandial insulin aspart in a treat-to-target, randomized controlled trial in children 1-17 yr with type 1 diabetes, for 26 wk (n = 350), followed by a 26-wk extension (n = 280). Participants were randomized to receive either IDeg once daily at the same time each day or IDet given once or twice daily according to local labeling. Aspart was titrated according to a sliding scale or in accordance with an insulin:carbohydrate ratio and a plasma glucose correction factor. Randomization was age-stratified: 85 subjects 1-5 yr. (IDeg: 43), 138 6-11 yr (IDeg: 70) and 127 12-17 yr (IDeg: 61) were included. Baseline characteristics were generally similar between groups overall and within each stratification. Non-inferiority of IDeg vs. IDet was confirmed for HbA1c at 26 wk; estimated treatment difference (ETD) 0.15% [-0.03; 0.32]95% CI . At 52 wk, HbA1c was 7.9% (IDeg) vs. 7.8% (IDet), NS; change in mean FPG was -1.29 mmol/L (IDeg) vs. +1.10 mmol/L (IDet) (ETD -1.62 mmol/L [-2.84; -0.41]95% CI , p = 0.0090) and mean basal insulin dose was 0.38 U/kg (IDeg) vs. 0.55 U/kg (IDet). The majority of IDet treated patients (64%) required twice-daily administration to achieve glycemic targets. Hypoglycemia rates did not differ significantly between IDeg and IDet, but confirmed and severe hypoglycemia rates were numerically higher with IDeg (57.7 vs. 54.1 patient-years of exposure (PYE) [NS] and 0.51 vs. 0.33, PYE [NS], respectively) although nocturnal hypoglycemia rates were numerically lower (6.0 vs. 7.6 PYE, NS). Rates of hyperglycemia with ketosis were significantly lower for IDeg vs. IDet [0.7 vs. 1.1 PYE, treatment ratio 0.41 (0.22; 0.78)95% CI , p = 0.0066]. Both treatments were well tolerated with comparable rates of adverse events. IDeg achieved equivalent long-term glycemic control, as measured by HbA1c with a significant FPG reduction at a 30% lower basal insulin dose when compared with IDet. Rates of hypoglycemia did not differ significantly between the two treatment groups; however, hyperglycemia with ketosis was significantly reduced in those treated with IDeg.

Trial registration: ClinicalTrials.gov NCT01513473.

Keywords: adolescents; children; insulin degludec; type 1 diabetes.

© 2015 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.

Figures

Fig 1
Fig 1
Participant disposition. IDeg, insulin degludec; IDet, insulin detemir.
Fig 2
Fig 2
Mean HbA1c over time (panel A) mean FPG over time (panel B) and mean 8-point SMPG profiles at wk 0 and wk 56 (panel C). Mean values with error bars (standard error of the mean) based on full analysis set and last observation carried forward imputed data. P-values are from an ANCOVA model. IDeg, insulin degludec; IDet, insulin detemir, SMPG, self-measured plasma glucose.
Fig 3
Fig 3
Mean basal insulin dose over time. Mean values based on full analysis set and last observation carried forward imputed data. IDeg, insulin degludec; IDet, insulin detemir.
Fig 4
Fig 4
Cumulative rates of confirmed (A) and nocturnal confirmed (B) hypoglycaemia. Mean values based on safety analysis set and last observation carried forward imputed data. IDeg, insulin degludec; IDet, insulin detemir.
Fig 5
Fig 5
Rate of hyperglycemia with ketosis. Mean values with error bars (standard error of the mean) based on full analysis set and last observation carried forward imputed data. P-values are from an ANCOVA model. IDeg, insulin degludec; IDet, insulin detemir.

References

    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:979–986.
    1. The Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1415–1427.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–389.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–2569.
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
    1. Halvorson M, Yasuda P, Carpenter S, Kaiserman K. Unique challenges for paediatric patients with diabetes. Diabetes Spectr. 2005;18:167–173.
    1. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(Suppl. 20):102–114.
    1. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes sourcebook authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–2054.
    1. Desrocher M, Rovet J. Neurocognitive correlation of type 1 diabetes mellitus in childhood. Neuropsychol Dev. 2004;10:36–52.
    1. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(Suppl. 12):134–145.
    1. Wolfsdorf J ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(Suppl. 20):154–179.
    1. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Diabetes Audit and Research in Tayside Scotland Medicines Monitoring Unit. Lancet. 1997;350:1505–1510.
    1. Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA. 2002;287:2511–2518.
    1. European Medicines Agency. Lantus® Summary of product characteristics (available from .
    1. European Medicines Agency. Levemir® Summary of product characteristics (available from .
    1. Heise T, Hovelmann U, Nosek L, Bottcher S, Granhall C, Hahhr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60(Suppl. 1A):LB11. (Abstract)
    1. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–864.
    1. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800.
    1. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal–Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–1497.
    1. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily. A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858–864.
    1. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–1162.
    1. World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009;107:403–405.
    1. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice. J Postgrad Med. 2001;47:199–203.
    1. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25:876–882.
    1. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289:1–16.
    1. Food and Drug Administration. Guidance for Industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft Guidance 2008 Rockville, MD: US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) [online] (available from ). Accessed February 21, 2012.
    1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–2114.
    1. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23:441–454.
    1. Le Floch JP, Lévy M, Mosnier-Pudar H, et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT) Diabetes Care. 2009;32:32–37.
    1. Biester T, Blaesig S, Remus K, et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2014;15:27–33.
    1. American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–1249.
    1. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultralong acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal–Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498–1507.
    1. Bode B, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal–Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30:1293–1297.
    1. Davies M, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–930.
    1. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21:1477–1483.
    1. Frier BM. Hypoglycaemia and cognitive function in diabetes. Int J Clin Pract Suppl. 2001;123:30–37.
    1. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. J Clin Endocrinol Metab. 2013;98:1845–1859.
    1. European Medicines Agency. Tresiba® Summary of product characteristics (available from

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj